Related Experiment Video

Updated: Jul 2, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

Telomerase as a universal tumor antigen for cancer vaccines

Gregory L Beatty1, Robert H Vonderheide

  • 1Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRBII/III, 421 Curie Boulevard, Philadelphia, PA 19104, USA.

Expert Review of Vaccines
|September 5, 2008
PubMed

Insights

Telomerase, a universal tumor antigen (hTERT), is being explored for cancer immunotherapy. Clinical trials show hTERT vaccines safely induce immune responses, paving the way for broad-spectrum cancer treatment and prevention.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • T-cell immunotherapy effectiveness is limited by heterogeneous tumor antigen expression.
  • Telomerase is a universal tumor antigen expressed in most cancers and crucial for oncogenic transformation.
  • Human telomerase reverse transcriptase (hTERT) is the catalytic subunit of telomerase and a target for cancer vaccines.

Purpose of the Study:

  • To investigate human telomerase reverse transcriptase (hTERT) as a broadly applicable immunological target for cancer immunotherapy.
  • To evaluate the safety and efficacy of hTERT-based cancer vaccines in clinical trials.
  • To explore strategies for enhancing cellular immunity against hTERT without toxicity.

Main Methods:

  • Identification of epitopes within human telomerase reverse transcriptase (hTERT).
  • Basic immunological analyses to assess hTERT immunogenicity.
  • Conducting initial clinical trials with multiple hTERT vaccine formulations.

Main Results:

  • hTERT has been confirmed as an immunogenic tumor antigen.
  • hTERT-specific immune responses were safely induced in patients during clinical trials.
  • hTERT-specific immune responses demonstrated an impact on clinical outcomes.

Conclusions:

  • hTERT represents a promising target for broad-spectrum cancer immunotherapy.
  • Second-generation vaccines are being developed to enhance anti-hTERT cellular immunity safely.
  • Findings may inform future cancer immunoprevention strategies.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...